Supernus Pharmaceuticals (SUPN) shares fell over 20% in Wednesday's premarket activity after the company said overnight its phase 2b study of SPN-820 in adults with treatment-resistant depression "did not" demonstrate a statistically significant improvement on the primary endpoint.
There was no treatment difference between SPN-820 and placebo in the change from baseline to week 4 for the secondary endpoints, the company said late Tuesday.
The multi-center, double-blind trial examined the efficacy and safety of SPN-820 over four weeks of treatment and then a week of "blinded placebo-washout" in about 250 patients from roughly 40 clinical sites.
Price: 31.71, Change: -8.04, Percent Change: -20.23
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。